These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24754260)

  • 21. Early diet intervention to reduce the incidence of hepatic encephalopathy in cirrhosis patients: post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) findings.
    Luo L; Fu S; Zhang Y; Wang J
    Asia Pac J Clin Nutr; 2016; 25(3):497-503. PubMed ID: 27440683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.
    Lv XH; Liu HB; Wang Y; Wang BY; Song M; Sun MJ
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1547-53. PubMed ID: 19686416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF).
    Cordoba J; Ventura-Cots M; Simón-Talero M; Amorós À; Pavesi M; Vilstrup H; Angeli P; Domenicali M; Ginés P; Bernardi M; Arroyo V;
    J Hepatol; 2014 Feb; 60(2):275-81. PubMed ID: 24128414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Splenic vein embolization as a feasible treatment for patients with hepatic encephalopathy related to large spontaneous splenorenal shunts.
    Ke Q; Wang Z; Huang X; Li L; Wu W; Qiu L; Jiao Y; Xie Y; Peng X; Liu J; Guo W
    Ann Hepatol; 2022; 27(5):100725. PubMed ID: 35623551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease.
    Stewart CA; Malinchoc M; Kim WR; Kamath PS
    Liver Transpl; 2007 Oct; 13(10):1366-71. PubMed ID: 17520742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
    Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.
    Nardelli S; Lattanzi B; Torrisi S; Greco F; Farcomeni A; Gioia S; Merli M; Riggio O
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):934-936. PubMed ID: 27816756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
    Riggio O; Masini A; Efrati C; Nicolao F; Angeloni S; Salvatori FM; Bezzi M; Attili AF; Merli M
    J Hepatol; 2005 May; 42(5):674-9. PubMed ID: 15826716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.
    Kaplan DE; Dai F; Aytaman A; Baytarian M; Fox R; Hunt K; Knott A; Pedrosa M; Pocha C; Mehta R; Duggal M; Skanderson M; Valderrama A; Taddei TH;
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2333-41.e1-6. PubMed ID: 26188137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different scoring systems in predicting survival in Chinese patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic shunt.
    Zhang F; Zhuge Y; Zou X; Zhang M; Peng C; Li Z; Wang T
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):853-60. PubMed ID: 24915489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
    Jepsen P; Watson H; Andersen PK; Vilstrup H
    J Hepatol; 2015 Nov; 63(5):1133-8. PubMed ID: 26206073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esophageal Cancer Surgery for Patients with Concomitant Liver Cirrhosis: A Single-Center Matched-Cohort Study.
    Valmasoni M; Pierobon ES; De Pasqual CA; Zanchettin G; Moletta L; Salvador R; Costantini M; Ruol A; Merigliano S
    Ann Surg Oncol; 2017 Mar; 24(3):763-769. PubMed ID: 27704371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
    Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic hepatic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt.
    Pomier-Layrargues G; Huet PM; Infante-Rivard C; Villeneuve JP; Marleau D; Duguay L; Tanguay S; Lavoie P
    Hepatology; 1988; 8(6):1506-10. PubMed ID: 3192163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG.
    Zhang M; Wang G; Zhao L; Wu Z; Zhang W; Zhang C
    Scand J Gastroenterol; 2016 Dec; 51(12):1502-1506. PubMed ID: 27379704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
    Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
    Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis].
    Zhang JY; Kuai JH; Jia JD; Wang BE; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):263-5. PubMed ID: 19403023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
    Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.
    Laleman W; Simon-Talero M; Maleux G; Perez M; Ameloot K; Soriano G; Villalba J; Garcia-Pagan JC; Barrufet M; Jalan R; Brookes J; Thalassinos E; Burroughs AK; Cordoba J; Nevens F;
    Hepatology; 2013 Jun; 57(6):2448-57. PubMed ID: 23401201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Embolization of spontaneous portosystemic shunts as treatment for refractory hepatic encephalopathy].
    Benítez C; Muñoz A; Poniachik J; Ramírez F; Muñoz C; Cermenati T; Martínez N; Díaz P; Meneses L
    Rev Med Chil; 2022 Jul; 150(7):879-888. PubMed ID: 37906821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.